BiotechTube

Avelumab + Lenvatinib

Phase 1Active
1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Central Nervous System Tumors

Conditions

Central Nervous System Tumors

Trial Timeline

Dec 3, 2021 → Sep 30, 2026

NCT ID
NCT05081180

About Avelumab + Lenvatinib

Avelumab + Lenvatinib is a phase 1 stage product being developed by Merck for Central Nervous System Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05081180. Target conditions include Central Nervous System Tumors.

What happened to similar drugs?

4 of 20 similar drugs in Central Nervous System Tumors were approved

Approved (4) Terminated (2) Active (14)
🔄Placebo + MirogabalinDaiichi SankyoPhase 3
✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄Leuprolide Acetate (LA)AbbViePhase 3
🔄temozolomideMerckPhase 3
🔄ranibizumab + ranibizumabNovartisPhase 3
🔄Ranibizumab 0.5 mgNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05081180Phase 1Active

Competing Products

20 competing products in Central Nervous System Tumors

See all competitors
ProductCompanyStageHype Score
Placebo + MirogabalinDaiichi SankyoPhase 3
40
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
29
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
43
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcoholEisaiPhase 1
29
perampanelEisaiPhase 2
35
Tirabrutinib + PlaceboOno PharmaceuticalPhase 2
42
TirabrutinibOno PharmaceuticalPhase 1
36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + VincristineOno PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
Tirabrutinib + Tirabrutinib + TirabrutinibOno PharmaceuticalPhase 2
39
pemetrexedEli LillyPhase 1
29
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
42
Leuprolide Acetate (LA)AbbViePhase 3
40
AcalabrutinibAstraZenecaPhase 2
39
Durvalumab + AcalabrutinibAstraZenecaPhase 1
33
temozolomideMerckPhase 3
44
Ibrutinib + Pembrolizumab + RituximabMerckPhase 1/2
39
TemozolomideMerckPhase 2
35
Verteporfin + ranibizumabNovartisPhase 1/2
32